CA2253463A1 - Derives de benzodizocine a substitution 8-hydrocarbyle, leur preparation et leur utilisation comme modulateurs de la proteine kinase c (pkc) - Google Patents

Derives de benzodizocine a substitution 8-hydrocarbyle, leur preparation et leur utilisation comme modulateurs de la proteine kinase c (pkc) Download PDF

Info

Publication number
CA2253463A1
CA2253463A1 CA002253463A CA2253463A CA2253463A1 CA 2253463 A1 CA2253463 A1 CA 2253463A1 CA 002253463 A CA002253463 A CA 002253463A CA 2253463 A CA2253463 A CA 2253463A CA 2253463 A1 CA2253463 A1 CA 2253463A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
mixture
compounds
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002253463A
Other languages
English (en)
Inventor
Dawei Ma
Alan P. Kozikowski
Robert I. Glazer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2253463A1 publication Critical patent/CA2253463A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D245/06—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composés de la formule (I) et leurs sels pharmaceutiquement acceptable. Dans ladite formule, R¿1? est H, alkyle(C¿1?-C¿5?), OR?a¿, SR?a¿, N(R?a¿)(R?b¿), halo, NO¿2?, NHC(O)[(C¿1?-C¿4?)alkyle] ou NHOH; R¿2? est un groupe (C¿5?-C¿22?) hydrocarbyle comprenant éventuellement 1-3 liaisons doubles, 1-2 liaisons triples ou un mélange de ces deux configurations, ou un aryl(C¿6?-C¿12?))alkyle (C¿2?-C¿10?), la fraction alkyle comprenant éventuellement 1-2 liaisons doubles, 1-2 liaisons triples ou un mélange de ces configurations; ce groupe hydrocarbyle (C¿5?-C¿22?) ou ce groupe aryl(C¿6?-C¿12?)alkyle (C¿2?-C¿10?) pouvant éventuellement être substitué par 1 ou 2 substituts choisis indépendamment dans le groupe comprenant halo, hydroxy, cyano, nitro, alkyle (C¿1?-C¿5?), alcoxy (C¿1?-C¿5?), trifluorométhyle, trifluorométhoxy, -C(=O)O alkyle (C¿1?-C¿5?) et N(R?e¿)(R?f¿); R¿1? et R¿2? ensemble constituent -CH(R?c¿)-CH¿2?-C(O)-N(R?d¿)-, -C(R?c¿)=CH-C(O)N(R?d¿)-, -C(R?c¿)=CH-N(R?d¿)- ou -C(R?c¿)=CH-O-; R¿3? est H, OH ou halo; R?a¿ et R?b¿ sont indépendamment H ou alkyle (C¿1?-C¿5?); R?c¿ est un groupe hydrocarbyle (C¿5?-C¿22?); R?d¿ est H ou alkyle (C¿1?-C¿5?); R?e¿ et R?f¿ sont indépendamment hydrogène, alkyle (C¿1?-C¿5?) ou alcanoyle (C¿1?-C¿5?), ou constituent avec l'azote auquel ils sont fixés pyrrolidino, pipéridino ou morpholino; Z est H ou alkyle (C¿1?-C¿5?); et Y est H ou alkyle (C¿1?-C¿5?). Ces substances sont des modulateurs de PKC et sont utiles au traitement, notamment, du cancer chez les mammifères. Sont également décrits des compositions pharmaceutiques constituées de composés de la formule (I), des procédés de préparation de composés de la formule (I), et des intermédiaires utiles dans la préparation de composés de formule (I).
CA002253463A 1996-05-10 1997-05-09 Derives de benzodizocine a substitution 8-hydrocarbyle, leur preparation et leur utilisation comme modulateurs de la proteine kinase c (pkc) Abandoned CA2253463A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1753296P 1996-05-10 1996-05-10
US60/017,532 1996-05-10

Publications (1)

Publication Number Publication Date
CA2253463A1 true CA2253463A1 (fr) 1997-11-20

Family

ID=21783129

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002253463A Abandoned CA2253463A1 (fr) 1996-05-10 1997-05-09 Derives de benzodizocine a substitution 8-hydrocarbyle, leur preparation et leur utilisation comme modulateurs de la proteine kinase c (pkc)

Country Status (5)

Country Link
EP (1) EP0918757A1 (fr)
JP (1) JP2000510149A (fr)
AU (1) AU3066697A (fr)
CA (1) CA2253463A1 (fr)
WO (1) WO1997043268A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065205A1 (en) 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
EP1915145A1 (fr) 2005-07-29 2008-04-30 Blanchette Rockefeller Neurosciences Institute Utilisation d'un activateur de pkc seul ou combine a un inhibiteur de pkc pour renforcer la memoire a long terme
CA2659242C (fr) 2006-07-28 2015-08-11 Blanchette Rockefeller Neurosciences Institute Procedes de stimulation de la croissance cellulaire, du remodelage synaptique et de la consolidation de la memoire a long terme
CA2864550C (fr) 2007-02-09 2018-07-10 Blanchette Rockefeller Neurosciences Institute Effets therapeutiques de bryostatines, de bryologues et d'autres substances apparentees sur l'alteration de la memoire induite par une ischemie/un accident vasculaire cerebral et une lesion cerebrale
EP3332797A3 (fr) 2007-02-09 2018-08-01 Blanchette Rockefeller Neurosciences Institute Effets thérapeutiques des bryostatines, bryologues et autres substances apparentées sur les troubles de la mémoire et les lésions cérébrales suite à un traumatisme crânien
WO2012006516A2 (fr) 2010-07-08 2012-01-12 Alkon Daniel L Activateurs de la protéine kinase c indirects et de type dag et anticoagulant pour le traitement de l'accident vasculaire cérébral
US20160025704A1 (en) 2013-03-15 2016-01-28 Daniel L. Alkon Methods for identifying neuroprotective pkc activators
US9833435B2 (en) 2014-03-27 2017-12-05 Blanchette Rockefeller Neurosciences Institute Compositions and methods to treat Niemann-Pick disease
WO2017099591A1 (fr) 2015-12-07 2017-06-15 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Traitement de cancers à mutation braf résistants aux inhibiteurs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009160A1 (fr) * 1993-09-30 1995-04-06 Shionogi & Co., Ltd. Derive de benzolactame
WO1996040614A1 (fr) * 1995-06-07 1996-12-19 Procyon Pharmaceuticals, Inc. Modulateurs .x. de proteine kinase c

Also Published As

Publication number Publication date
EP0918757A1 (fr) 1999-06-02
JP2000510149A (ja) 2000-08-08
AU3066697A (en) 1997-12-05
WO1997043268A1 (fr) 1997-11-20

Similar Documents

Publication Publication Date Title
US11065234B2 (en) Estrogen receptor modulators
CA2253463A1 (fr) Derives de benzodizocine a substitution 8-hydrocarbyle, leur preparation et leur utilisation comme modulateurs de la proteine kinase c (pkc)
EP1074542B1 (fr) Composes indoles contenant un sulfonamide
WO2008147713A1 (fr) Inhibiteurs de souligné de wnt et procédés de préparation et d'utilisation de ceux-ci
US10730864B2 (en) RAD51 inhibitors and uses thereof
EA021983B1 (ru) Производные диоксабицикло[3.2.1]октан-2,3,4-триола
EA018225B1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA008058B1 (ru) Цитотоксические агенты, содержащие новые сильнодействующие таксаны, и их терапевтическое применение
JPH0826036B2 (ja) 生理活性物質ｋ−２５２の誘導体
KR20200012316A (ko) 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
CN105263924A (zh) Cxcr7受体调节剂
BRPI0612542A2 (pt) derivados de indol com atividade antitumoral
Patel et al. Recent progress in histone deacetylase (HDAC) 1 inhibitors as anticancer agent
AU2007249952A1 (en) Modified chalcone compounds as antimitotic agents
US20120258993A1 (en) Non-natural macrocyclic amide hdac6 inhibitor compounds and their uses as therapeutic agents
US20040018995A1 (en) Derivatives of monosaccharides as cell adhesion inhibitors
CN114539237B (zh) Ido抑制剂、制备方法、药物组合物和应用
US6677456B2 (en) Pentacyclic taxan compound
Baraldi et al. Heterocyclic analogs of DNA minor groove alkylating agents
EP3400210B1 (fr) Composés"multi-cibles"à activité inhibitrice des histone-désacétylases et de la polymérisation de la tubuline pour son utilisation dans le traitement du cancer
WO2021227440A1 (fr) Classe de dérivés arylglucosides, leur procédé de préparation et application associée
CA2752198C (fr) Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique
Gros et al. Modular construction of quaternary hemiaminal-based inhibitor candidates and their in cellulo assessment with HIV-1 protease
Zhu et al. Design, synthesis, and biological evaluation of novel spirocyclic compounds as potential anti-glioblastoma agents
Rojas-Rousseau et al. Synthesis of a new structural analogue of (+)-porothramycin

Legal Events

Date Code Title Description
FZDE Dead